FDAsafety guidance66% confidence
FDA AP — SARCLISA ESCENA (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Amgen; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application BLA761445. Sponsor: SANOFI-AVENTIS U.S. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ISATUXIMAB-IRFC.
Supporting Context
- Therapeutic area
- Cardiovascular · PCSK9 Inhibitor
- Sub-indication
- General
Related signal: FDA Accepts Supplement for Repatha (Evolocumab) by Amgen